Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Endotracheal application of ultraviolet A light in critically ill severe acute respiratory syndrome coronavirus-2 patients: A first-in-human study

View ORCID ProfileAli Rezaie, Gil Y. Melmed, Gabriela Leite, View ORCID ProfileRuchi Mathur, Will Takakura, Isabel Pedraza, Michael Lewis, Rekha Murthy, George Chaux, View ORCID ProfileMark Pimentel
doi: https://doi.org/10.1101/2021.03.05.21252997
Ali Rezaie
1Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles
2Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ali Rezaie
  • For correspondence: ali.rezaie@cshs.org
Gil Y. Melmed
2Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriela Leite
1Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruchi Mathur
1Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles
3Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Cedars-Sinai, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ruchi Mathur
Will Takakura
4Division of General Internal Medicine, Department of Medicine, Cedars-Sinai, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabel Pedraza
5Division of Pulmonary and Critical Care Medicine, Department of Medicine, Cedars-Sinai, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Lewis
5Division of Pulmonary and Critical Care Medicine, Department of Medicine, Cedars-Sinai, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rekha Murthy
6Division of Infectious Diseases, Department of Medicine, Cedars-Sinai, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Chaux
6Division of Infectious Diseases, Department of Medicine, Cedars-Sinai, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Pimentel
1Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles
2Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark Pimentel
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Promising preclinical experiments show that, under specific and monitored conditions, ultraviolet-A (UVA) exposure reduces certain bacteria, fungi, and viruses including coronavirus-229E without harming mammalian columnar epithelial cells. We aimed to evaluate the safety and effects of UVA therapy administered by a novel device via endotracheal tube in critically ill subjects with SARS-CoV-2 infection.

Methods Five newly intubated mechanically ventilated adults with SARS-CoV-2 infection, with an endotracheal tube size 7.5mm or greater, were treated with UVA for 20 minutes daily for 5 days, and followed for 30 days.

Results Five subjects were enrolled (mean age 56.6yrs, 3 male). At baseline, all subjects scored 9/10 on the WHO clinical severity scale (10=death) with predicted mortality ranging from 21 to 95%. Average log changes in endotracheal viral load from baseline to day 5 and day 6 were -2.41 (range -1.16 to -4.54; Friedman P=0.002) and -3.20 (range -1.20 to -6.77; Friedman P<0.001), respectively. There were no treatment-emergent adverse events. One subject died 17 days after enrollment due to intracranial hemorrhagic complications of anticoagulation while receiving extracorporeal membrane oxygenation. The remaining subjects clinically improved and scored 2, 4, 5, and 7 on the WHO scale at day 30. In these subjects, the slope of viral load reduction during UVA treatment correlated with the slope of improvement in clinical WHO severity score over time (Spearman rho=1, P<0.001).

Conclusion In this first-in-human study, endotracheal UVA therapy under specific and monitored settings, was safe with a significant reduction in respiratory SARS-CoV-2 viral burden over the treatment period.

Trial Registration ClinicalTrials.gov #NCT04572399.

Key Messages

  • What is the key question?

    Can endotracheal narrow-band UVA therapy be a safe and effective treatment for severe SARS-CoV-2 infection?

  • What is the bottom line?

    Under specific and monitored settings, endotracheal UVA light therapy may be an effective treatment for SARS-CoV-2 infection. Endotracheal UVA light therapy appears to be well tolerated in critically ill patients with SARS-CoV-2 infection.

  • Why read on?

    This is the fist-in-human trial of internal UVA therapy using a alternative novel approach to combat COVID-19.

Competing Interest Statement

This investigator-initiated study was sponsored by Aytu Biosciences. Cedars-Sinai Medical Center has a licensing agreement with Aytu BioSciences. Cedars-Sinai has a patent on internal UV therapy, inventors: AR, MP, GYM, RM and GL. All other authors do not have any relevant conflict of interest. None of the authors receive salary or consulting fees or have any equity, shares, or options at Aytu Biosciences.

Clinical Trial

NCT04572399

Funding Statement

This investigator-initiated study was sponsored by Aytu Biosciences. The study sponsor had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review, and approval of the manuscript, or the decision to submit the manuscript for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial protocol was approved by the institutional review board of Cedars-Sinai, Los Angeles, CA, USA

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data are in the manuscript and supporting files

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 08, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Endotracheal application of ultraviolet A light in critically ill severe acute respiratory syndrome coronavirus-2 patients: A first-in-human study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Endotracheal application of ultraviolet A light in critically ill severe acute respiratory syndrome coronavirus-2 patients: A first-in-human study
Ali Rezaie, Gil Y. Melmed, Gabriela Leite, Ruchi Mathur, Will Takakura, Isabel Pedraza, Michael Lewis, Rekha Murthy, George Chaux, Mark Pimentel
medRxiv 2021.03.05.21252997; doi: https://doi.org/10.1101/2021.03.05.21252997
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Endotracheal application of ultraviolet A light in critically ill severe acute respiratory syndrome coronavirus-2 patients: A first-in-human study
Ali Rezaie, Gil Y. Melmed, Gabriela Leite, Ruchi Mathur, Will Takakura, Isabel Pedraza, Michael Lewis, Rekha Murthy, George Chaux, Mark Pimentel
medRxiv 2021.03.05.21252997; doi: https://doi.org/10.1101/2021.03.05.21252997

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (412)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (156)
  • Dermatology (97)
  • Emergency Medicine (247)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
  • Epidemiology (8534)
  • Forensic Medicine (4)
  • Gastroenterology (381)
  • Genetic and Genomic Medicine (1739)
  • Geriatric Medicine (167)
  • Health Economics (370)
  • Health Informatics (1234)
  • Health Policy (618)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (369)
  • Infectious Diseases (except HIV/AIDS) (10271)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1666)
  • Nursing (97)
  • Nutrition (247)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (925)
  • Ophthalmology (262)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (110)
  • Palliative Medicine (40)
  • Pathology (249)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (246)
  • Primary Care Research (205)
  • Psychiatry and Clinical Psychology (1757)
  • Public and Global Health (3825)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (317)
  • Respiratory Medicine (518)
  • Rheumatology (207)
  • Sexual and Reproductive Health (164)
  • Sports Medicine (156)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (100)
  • Urology (74)